Stockscreener 앱 받기
0.685
4.44%
0.0291
시간 외 거래:
.68
-0.005
-0.73%
Lexicon Pharmaceuticals Inc 주식(LXRX)의 최신 뉴스
Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference | LXRX Stock News - GuruFocus
Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference - The Manila Times
Lexicon Pharmaceuticals Announces Exclusive Fireside Chat at HC Wainwright BioConnect Conference - Stock Titan
Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 - The Manila Times
Lexicon Pharmaceuticals Sets Q1 2025 Earnings Date: Key Financial Updates Coming May 13 - Stock Titan
Carcinoid Syndrome Diarrhea Treatment Market To Reach US$ - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Lexicon Pharmaceuticals, Inc. (LXRX)Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action & Lead Plaintiff Deadline: April 1, 2019 - ACCESS Newswire
Top 2 Health Care Stocks That May Crash This Month - Benzinga
Form ARS LEXICON PHARMACEUTICALS, For: Dec 31 - StreetInsider
Lexicon Pharmaceuticals at Needham Conference: Strategic Shift in Focus By Investing.com - Investing.com Canada
Novo Nordisk inks licensing pact with Lexicon for obesity candidate - MSN
LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? - MSN
Lexicon Pharmaceuticals to present at Healthcare Conference By Investing.com - Investing.com South Africa
Lexicon Pharmaceuticals to present at Healthcare Conference - Investing.com
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Lexicon Pharma (LXRX) to Present at the 24th Annual Needham Virtual Healthcare Conference - StreetInsider
Promising Penny Stocks To ResearchMarch 29th - MarketBeat
Social Buzz: Wallstreetbets Stocks Mixed Premarket Tuesday; Tesla to Advance, Lexicon Pharmaceuticals to Decline - MarketScreener
Lexicon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:LXRX) - MarketBeat
Novo, Merck each pay $200M for pipeline additions: Deals Report - biocentury.com
Novo Nordisk gains rights to novel small molecule inhibitor - European Pharmaceutical Review
Houston-area company inks massive $1B deal for weight-loss drug - Chron
Novo Nordisk licenses Lexicon’s preclinical obesity drug in $1B deal - BioWorld MedTech
US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst - Benzinga
Biotech Firms Celebrate Gains With Promising Trials And Partnerships - Finimize
The Woodlands-based company strikes obesity-drug license deal worth up to $1B - KHOU
Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) - Seeking Alpha
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 - Investor's Business Daily
What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals - Fidelity
Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s - MedCity News
Lexicon Pharmaceuticals, Novo Nordisk strike obesity-drug license deal worth up to $1B - The Business Journals
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug - Yahoo Finance
Lexicon (LXRX) Secures $1 Billion Deal with Novo Nordisk for Obe - GuruFocus
Novo Adds Lexicon’s Novel Obesity Drug To Deal Flurry - insights.citeline.com
Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal - Reuters
Lexicon Pharmaceuticals: Strategic Partnerships and Pipeline Advancements Drive Buy Rating - TipRanks
Lexicon Pharma soars as it licenses LX9851 to Novo Nordisk - The Pharma Letter
Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected - Benzinga
Lexicon inks $1 billion deal with Novo Nordisk for obesity drug By Investing.com - Investing.com South Africa
Lexicon stock rises on Novo Nordisk licensing deal (LXRX) - Seeking Alpha
Sector Update: Health Care Stocks Steady Premarket Friday - MarketScreener
Lexicon Pharmaceuticals (LXRX) Soars 95% on Novo Nordisk Licensi - GuruFocus.com
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk - Benzinga
0.88%
2.05%
자본화:
|
볼륨(24시간):